| Summary: | 碩士 === 國立臺灣大學 === 臨床醫學研究所 === 100 === Objectives: Myostatin, a negative regulator of skeletal muscle growth, may modulate muscle in myopathy after development.
Background: Both hypothyroidism and hyperthyroidism may cause signs and symptoms of neuromuscular dysfunction. We hypothesized that serum myostatin level might be related to myopathy in hyperthyroidism.
Method: We measure serum myostatin level in patients with hyperthyroidism and normal control, and check serum myostatin again after anti-thyroid drugs used in patients with hyperthyroidism for 24 weeks. .
Results There is no elevation of serum myostatin level but elevated serum IGF-1 level, compared to euthyroidism. After anti-thyroid medication for 24 weeks, no significant increase of serum myostatin protein levels was found and the serum IGF-1 level also had no obvious change. 11 of 24 patients have decrease of serum myostatin protein levels after medication for 24 weeks
Conclusions： There are no changes in myostatin level before and after medication. Serum IGF-1 increase in patients with hyperthyroidism and no change after treatment. Advanced measurement of serum and muscle myostatin protein, myostatin mRNA, follistatin and other muscle related markers in more cases could be done.
|
|---|
